多发性大动脉炎治疗的新进展

摘要/Abstract

中图分类号:

R654.3

韩同磊, 孙羽东, 魏小龙, 赵志青, 景在平. 多发性大动脉炎治疗的新进展[J]. 外科理论与实践, 2020, 25(01): 79-82.

HAN Tonglei, SUN Yudong, WEI Xiaolong, ZHAO Zhiqing, JING Zaiping. New advance in treatment of Takayasu arteritis[J]. Journal of Surgery Concepts & Practice, 2020, 25(01): 79-82.

参考文献21

[22]	Salvarani C, Hatemi G. Management of large-vessel vasculitis[J]. Curr Opin Rheumatol, 2019, 31(1):25-31. doi:10.1097/BOR.0000000000000561pmid:30461542
[23]	Muratore F, Pipitone N, Salvarani C. Standard and biolo-gical treatment in large vessel vasculitis: guidelines and current approaches[J]. Expert Rev Clin Immunol, 2017, 13(4):345-360.
[24]	Ferfar Y, Mirault T, Desbois AC, et al. Biotherapies in large vessel vasculitis[J]. Autoimmun Rev, 2016, 15(6):544-551. doi:10.1016/j.autrev.2016.02.012pmid:26883459
[25]	De Franciscis S, Serra R, Luongo A, et al. The management of Takayasu's arteritis: personal experience[J]. Ann Vasc Surg, 2007, 21(6):754-760. pmid:17512164
[26]	Keser G, Aksu K. What is new in management of Takayasu arteritis?[J]. Presse Med, 2017, 46(7-8 Pt 2):e229-e235.
[27]	Mekinian A, Comarmond C, Resche-Rigon M, et al. Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients[J]. Circulation, 2015, 132(18):1693-1700. doi:10.1161/CIRCULATIONAHA.114.014321pmid:26354797
[28]	Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of Takayasu arteritis[J]. Rheumatology (Oxford), 2018, 57(12):2101-2105. doi:10.1093/rheumatology/key197pmid:30010945
[29]	Gudbrandsson B, Molberg O, Palm O. TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study[J]. Arthritis Res Ther, 2017, 19(1):99. doi:10.1186/s13075-017-1316-ypmid:28521841
[30]	Schmidt J, Kermani TA, Bacani AK, et al. Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup[J]. Arthritis Care Res (Hoboken), 2012, 64(7):1079-1083. doi:10.1002/acr.21636pmid:22328491
[31]	Molloy ES, Langford CA, Clark TM, et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up[J]. Ann Rheum Dis, 2008, 67(11):1567-1569. doi:10.1136/ard.2008.093260pmid:18677012
[32]	Lee YH, Song GG. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis[J]. Ann Rheum Dis, 2019, 78(1):e9.
[33]	Loricera J, Blanco R, Hernandez JL, et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review[J]. Clin Exp Rheumatol, 2016, 34(3 Suppl 97):S44-S53.
[34]	Risse J, Mandry D, Settembre N, et al. Dramatic response to tocilizumab before emergency surgery in severe active Takayasu disease[J]. Circ Cardiovasc Imaging, 2016, 9(7).pii: e004819.
[35]	Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis[J]. Arthritis Rheum, 2004, 50(4):1332-1337.
[36]	Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis[J]. Arthritis Rheumatol, 2017, 69(4):846-853.
[37]	Li J, Zhu M, Li M, et al. Cause of death in Chinese Takayasu arteritis patients[J]. Medicine (Baltimore), 2016, 95(27):e4069.
[38]	Lee BB. Simultaneous multiple bypass for Takayasu arteritis[J]. Eur J Vasc Endovasc Surg, 2018, 56(6):910.
[39]	Chen ZG, Chen YX, Diao YP, et al. Simultaneous multi-supra-aortic artery bypass successfully implemented in 17 patients with type Ⅰ Takayasu arteritis[J]. Eur J Vasc Endovasc Surg, 2018, 56(6):903-909.
[40]	冯睿, 魏小龙, 赵志青, 等. 采用单条大隐静脉行腹主动脉-双侧肾动脉旁路术治疗大动脉炎性肾动脉狭窄[J]. 外科理论与实践, 2011, 16(2):151-154.
[41]	Kim YW, Kim DI, Park YJ, et al. Surgical bypassvs. endovascular treatment for patients with supra-aortic arterial occlusive disease due to Takayasu arteritis[J]. J Vasc Surg, 2012, 55(3):693-700.
[42]	Mason JC. Surgical intervention and its role in Takayasu arteritis[J]. Best Pract Res Clin Rheumatol, 2018, 32(1):112-124.
[43]	Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients[J]. Mayo Clin Proc, 2013, 88(8):822-830. doi:10.1016/j.mayocp.2013.04.025pmid:23849994
[44]	Che W, Xiong H, Jiang X, et al. Stenting for middle aortic syndrome caused by Takayasu arteritis-immediate and long-term outcomes[J]. Catheter Cardiovasc Interv, 2018, 91(S1):623-631.
[45]	Hadjadj J, Canaud G, Mirault T, et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G[J]. Rheumatology (Oxford), 2018, 57(6):1011-1020. doi:10.1093/rheumatology/key017pmid:29506143
[46]	Saleh HM, Gabr AK, Tawfik MM, et al. Prospective, randomized study of cutting balloon angioplasty versus conventional balloon angioplasty for the treatment of hemodialysis access stenoses[J]. J Vasc Surg, 2014, 60(3):735-740.
[47]	Gumus B, Cevik H, Vuran C, et al. Cutting balloon angioplasty of bilateral renal artery stenosis due to Takayasu arteritis in a 5-year-old child with midterm follow-up[J]. Cardiovasc Intervent Radiol, 2010, 33(2):394-397.
[1]	Mirouse A, Biard L, Comarmond C, et al. Overall survival and mortality risk factors in Takayasu's arteritis: A multicenter study of 318 patients[J]. J Autoimmun, 2019, 96(1):35-39.
[2]	Xiao Y, Zhou J, Wei X, et al. Outcomes of different treatments on Takayasu's arteritis[J]. J Thorac Dis, 2016, 8(9):2495-2503. pmid:27747001
[3]	De Souza AW, De Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis[J]. J Autoimmun, 2014, 48(2):79-83.
[4]	Janarthanan M, Rathinasamy J. Aortic calcification in longstanding, undiagnosed Takayasu arteritis[J]. Lancet, 2018, 392(10151):950. doi:S0140-6736(18)31997-4pmid:30238890
[5]	Gomez L, Chaumet-Riffaud P, Noel N, et al. Effect of CRP value on F-FDG PET vascular positivity in Takayasu arteritis: a systematic review and per-patient based meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2018, 45(4):575-581.
[6]	Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients[J]. Circulation, 2017, 136(12):1114-1122. doi:10.1161/CIRCULATIONAHA.116.027094pmid:28701469
[7]	Park SJ, Kim HJ, Park H, et al. Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study[J]. Int J Cardiol, 2017, 235(5):100-104.
[8]	Gudbrandsson B, Molberg O, Garen T, et al. Prevalence, incidence, and disease characteristics of Takayasu arteritis by ethnic background: data from a large, population-based cohort resident in southern norway[J]. Arthritis Care Res (Hoboken), 2017, 69(2):278-285. doi:10.1002/acr.22931pmid:27159262
[9]	Hong C, Zeng T, Zhao J, et al. Takayasu's arteritis misdiagnosed as mediastinal malignant lymphoma: a case report and review of the literature[J]. J Thorac Dis, 2014, 6(6):E115-E119.
[10]	Aeschlimann FA, Barra L, Alsolaimani R, et al. Presentation and disease course of childhood-onset versus adult-onset Takayasu arteritis[J]. Arthritis Rheumatol, 2019, 71(2):315-323. doi:10.1002/art.40690
[11]	Watanabe Y, Miyata T, Tanemoto K. Current clinical features of new patients with Takayasu arteritis observed from cross-country research in japan: age and sex specificity[J]. Circulation, 2015, 132(18):1701-1709. doi:10.1161/CIRCULATIONAHA.114.012547pmid:26354799
[12]	Mwipatayi BP, Jeffery PC, Beningfield SJ, et al. Takayasu arteritis: clinical features and management: report of 272 cases[J]. ANZ J Surg, 2005, 75(3):110-117. pmid:15777385
[13]	Tyagi S, Bansal A, Gupta MD, et al. Endovascular ma-nagement of acute aortic dissection in Takayasu arteritis[J]. JACC Cardiovasc Interv, 2018, 11(12):e99-e101.
[14]	Park EH, Lee EY, Lee YJ, et al. Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study[J]. Rheumatol Int, 2018, 38(12):2233-2242. doi:10.1007/s00296-018-4159-1pmid:30229280
[15]	Goel R, Sathish KT, Danda D. Childhood-onset Takayasu arteritis (c-ta): current and future drug therapy[J]. Paediatr Drugs, 2019, 21(2):81-93.
[16]	Misra DP, Wakhlu A, Agarwal V, et al. Recent advances in the management of Takayasu arteritis[J]. Int J Rheum Dis, 2019, 22(1):60-68.
[17]	Samson M, Espigol-Frigole G, Terrades-Garcia N, et al. Biological treatments in giant cell arteritis & Takayasu arteritis[J]. Eur J Intern Med, 2018, 50(4):12-19.
[18]	Decker P, Olivier P, Risse J, et al. Tocilizumab and refractory Takayasu disease: Four case reports and syste-matic review[J]. Autoimmun Rev, 2018, 17(4):353-360. doi:S1568-9972(18)30034-Xpmid:29427826
[19]	Sanchez-Alvarez C, Koster M, Duarte-García A, et al. Disease progression of Takayasu arteritis in two patients treated with tocilizumab[J]. Ann Rheum Dis, 2018-12-08[Epub ahead of print].
[20]	Kong X, Zhang X, Lv P, et al. Treatment of Takayasu arteritis with the IL-6R antibody tocilizumabvs. cyclophosphamide[J]. Int J Cardiol, 2018, 266(9):222-228.
[48]	Tyagi S, Sarkar PG, Gupta MD, et al. Restoration of vision by endovascular revascularization in Takayasu arteritis: A case series[J]. J Cardiol Cases, 2018, 18(4):123-127.
[21]	Mekinian A, Resche-Rigon M, Comarmond C, et al. Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients[J]. J Autoimmun, 2018, 91(7):55-60.

多发性大动脉炎治疗的新进展

New advance in treatment of Takayasu arteritis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献21

相关文章15

编辑推荐

Metrics

本文评价

[1]	王远江, 邹浩.胆囊癌综合治疗的临床研究[J]. 外科理论与实践, 2023, 28(02): 171-176.
[2]	赵法之, 赵平.胃癌治疗手术中心论体系的形成与完善[J]. 外科理论与实践, 2023, 28(01): 24-30.
[3]	秘家学, 朱恒豪, 王端, 刘浩飞, 戴向晨.外分支支架和内分支支架治疗B型主动脉夹层的近期结果及计算流体力学分析[J]. 外科理论与实践, 2023, 28(01): 58-66.
[4]	原野, 周旻, 王恩慈, 李哲昀, 张宇翀, 林朋, 莫凡迪, 郭大乔, 符伟国, 王利新.真腔覆膜支架点状植入联合假腔内栓塞技术治疗腔内修复术后主动脉夹层动脉瘤[J]. 外科理论与实践, 2022, 27(05): 458-462.
[5]	杨玲, 查晴, 张倩茹, 叶佳雯, 杨克, 刘艳.钙化性主动脉瓣膜病的生物标志物预测模型的构建[J]. 内科理论与实践, 2022, 17(04): 324-329.
[6]	葛阳阳, 郭伟.主动脉夹层301分型概念及临床意义[J]. 外科理论与实践, 2022, 27(04): 281-283.
[7]	周旻, 王利新, 符伟国.主动脉夹层术后影像学随访进展及规范[J]. 外科理论与实践, 2022, 27(04): 284-287.
[8]	李震.2022年STS和AATS B型主动脉夹层指南解读[J]. 外科理论与实践, 2022, 27(04): 288-293.
[9]	王伦常, 舒畅.非A非B型主动脉夹层的腔内治疗[J]. 外科理论与实践, 2022, 27(04): 294-298.
[10]	陈梦泽, 李振江, 张鸿坤.腔内治疗A型主动脉夹层的难点与突破[J]. 外科理论与实践, 2022, 27(04): 299-303.
[11]	常光其, 杨文超.主动脉夹层合并灌注不良综合征[J]. 外科理论与实践, 2022, 27(04): 304-308.
[12]	王利新, 张宇翀, 符伟国.主动脉夹层术后远端动脉瘤的处理[J]. 外科理论与实践, 2022, 27(04): 309-314.
[13]	李晓晔, 陆清声.单分支支架腔内修复B型主动脉夹层[J]. 外科理论与实践, 2022, 27(04): 314-317.
[14]	付东生, 刘昭, 杨超, 李沁, 陈阁政, 孙莉莉, 李文东, 周敏捷, 刘晨, 乔彤, 李毅清, 李晓强.3D参数曲面平面拓扑导板在主动脉开窗/分支支架腔内修复技术中的临床应用[J]. 外科理论与实践, 2022, 27(04): 318-323.
[15]	王瑞华, 仇鹏, 刘俊超, 吴小雨, 秦金保, 叶开创, 李维敏, 刘晓兵, 殷敏毅, 黄新天, 陆信武.激光原位开窗胸主动脉腔内重建治疗累及弓部分支的主动脉夹层:近期结果及并发症[J]. 外科理论与实践, 2022, 27(04): 324-329.